Iram Meharban

• Assisted with strategic haematology accounts to support delivery and expansion of innovative therapies for patients with multiple myeloma.
• Contributed to launch of new indications for anti-CD38 monoclonal antibody & introduction of Bispecific Antibodies in the system by collaborating with haematology treatment centres to set up local services and increase usage among suitable patient groups.
• Supported engagement with consultant haematologists and MDT stakeholders to prepare centres for integration of bispecific antibody therapies in multiple myeloma treatment pathways.
• Developed relationships with haematology consultants, transplant teams, specialist nurses, and hospital pharmacists across major treatment centres.
• Coordinated with medical, market access, and commercial teams to align clinical evidence, local treatment protocols, and NHS pathways.
• Implemented strategic account plans to improve patient identification, referral pathways, and treatment capacity within centres across North West of England.

Managed specialist accounts across dermatology and rheumatology networks supporting biologic therapies for psoriasis and psoriatic arthritis.

Key Achievements:

• Drove adoption of advanced biologic therapies across secondary care dermatology and rheumatology networks.

• Built strong partnerships with consultant dermatologists, rheumatologists, specialist nurses and pharmacists.

• Developed strategic account plans aligned with NHS priorities to optimise biologic treatment pathways.

• Collaborated cross-functionally with medical and market access teams to strengthen clinical advocacy and formulary positioning.

• Mersey & Cheshire had limited sales in Psoriasis & Psoriatic Arthritis and by end of H2 2024 SVT of 130%.

• Responsible for product launch of breakthrough treatments in Mental Health for Treatment Resistant Depression & Schizophrenia.
• For Mental Health driving high engagement with key customers such as psychiatrists, chief pharmacists, community psychiatric nurses, lead nurses and service managers.
• Working with specialist schedule 2 controlled drug with special infrastructure requirements and getting agreement on infrastructure and patient identification for cohort use/ IFR use due to challenges with NICE Delays.
• Recognized for Successful Cross-Functional working with Health solutions Manager and Health Economics Liaison Manager.
• High level selling excellence in call observed in field visits and on call excellence days.
• Recognized for exceptional business planning on one page plans, stakeholder management plans, Cross-functional team working document & forecasting.
• Advocacy and KOL Development of customers at all levels.
• Other roles & Projects assigned: Aspiring Leaders Programme, Mentoring, Women’s Leadership Initiative, Digital Transformation & Talent & Development Focus Groups.

• Engaged with healthcare professionals to support sales efforts in Lancashire and Mersey for triple therapy treatment for severe COPD patients.
• Assisted with relaunch of treatment for uncontrolled asthma patients.
• Contributed to activation of new guidelines and worked towards overturning blacklisted formulary positions.
• Achieved majority market share (53%) within first year of launch vs key competitor in Mersey territory.

• Nominated for emerging talent & won Primary care specialist 2018 at Pf awards
• Post Launch of both Diabetes and Cardiovascular products but experience here of protecting formulary positioning & getting better positionings when guidance updated.
• Responsible for engaging with Secondary Care, CCG leads, MM & Diabetes Leads in Key accounts across Greater Manchester (Wigan, Bolton, Bury, HMR, Oldham & Tameside) to promote MSD Diabetes & CV portfolio and clinically differentiate products over competitors.
• Ensuring budget, time & resource is spent protecting & growing business and formulary positioning.
• Building Advocacy across Secondary care and utilising them at surgery speaker meetings and larger sole sponsorship exhibitions & evening speaker meetings.
• Ensuring alignment between company objectives and CCG objectives by studying local operational plans, priorities, and challenges.
• Working cross functionally with other business divisions such as Women’s Health, Vaccines and Cardiovascular Disease & Maximizing resources such as AHL’s and MSL’s with KOL’s and advocacy development in secondary care and GPwSI in primary care.
• Implementation of first Diabetes Nurse Forum, which was then replicated UK Wide.
• Strategic workings through discussions with APC members based in target Surgeries and effective targeting of key decision making units (Modality Partnership).
• Given responsibility by Regional Business Manager coaching and mentoring new starters (informal role).